Progress in vaccine development against Helicobacter pylori
- PMID: 17442014
- DOI: 10.1111/j.1574-695X.2007.00237.x
Progress in vaccine development against Helicobacter pylori
Abstract
Based on the very high prevalence of diseases caused by Helicobacter pylori, particularly in the developing world, and the rapid emergence of antibiotic resistance among clinical isolates, there is a strong rationale for an effective vaccine against H. pylori. In this review we describe recent promising candidate vaccines and prophylactic or therapeutic immunization strategies for use against H. pylori, as well as studies to identify immune responses that are related to protection in experimental animals. We also describe identification of different types of immune responses that may be related to protection against symptoms based on comparisons of H. pylori-infected patients with duodenal ulcers or gastric cancer and asymptomatic carriers. We conclude that there is still a strong need to clarify the main protective immune mechanisms against H. pylori as well as to identify a cocktail of strong protective antigens, or recombinant bacterial strains that express such antigens, that could be administered by a regimen that gives rise to effective immune responses in humans.
Similar articles
-
Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.Int J Med Microbiol. 2008 Jan;298(1-2):151-9. doi: 10.1016/j.ijmm.2007.07.006. Epub 2007 Aug 21. Int J Med Microbiol. 2008. PMID: 17714988 Review.
-
Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.Helicobacter. 2006 Apr;11(2):113-22. doi: 10.1111/j.1523-5378.2006.00385.x. Helicobacter. 2006. PMID: 16579841
-
The current status of Helicobacter pylori vaccines: a review.Helicobacter. 2007 Apr;12(2):89-102. doi: 10.1111/j.1523-5378.2007.00478.x. Helicobacter. 2007. PMID: 17309745 Review.
-
The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1883-9. doi: 10.1158/1055-9965.EPI-04-0775. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16103431 Review.
-
A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori.Vaccine. 2011 Feb 1;29(6):1235-41. doi: 10.1016/j.vaccine.2010.11.088. Epub 2010 Dec 13. Vaccine. 2011. PMID: 21147129
Cited by
-
Developing a potent vaccine against Helicobacter pylori: critical considerations and challenges.Expert Rev Mol Med. 2024 Nov 25;27:e12. doi: 10.1017/erm.2024.19. Expert Rev Mol Med. 2024. PMID: 39584502 Free PMC article. Review.
-
A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.Infect Immun. 2013 May;81(5):1532-40. doi: 10.1128/IAI.01407-12. Epub 2013 Feb 25. Infect Immun. 2013. PMID: 23439305 Free PMC article.
-
Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach.Infect Immun. 2010 Oct;78(10):4251-60. doi: 10.1128/IAI.00536-10. Epub 2010 Aug 9. Infect Immun. 2010. PMID: 20696831 Free PMC article.
-
Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.Helicobacter. 2023 Aug;28(4):e12997. doi: 10.1111/hel.12997. Epub 2023 Jun 14. Helicobacter. 2023. PMID: 37314018 Free PMC article.
-
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.Vaccine. 2010 Feb 3;28(5):1404-11. doi: 10.1016/j.vaccine.2009.10.147. Epub 2009 Nov 6. Vaccine. 2010. PMID: 19897067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical